← Back to Patent Explorer
US4606920A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical composition suitable for treatment of inflammatory changes of the bronchial mucosa

Assignee: Individual
•
Filing: 1984-03-02
•
Granted: 1986-08-19
•
Expires: 2004-03-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A pharmaceutical composition is being described that contains pharmacologically acceptable magnesium compounds, etofylline, vitamin A and vitamin C. It is especially suitable for treatment of inflammatory changes of the bronchial mucosa.

Inventors

  • 👤 Hans-Peter Walter

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 18:12
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K33/00; A61K33/06; A61K33/42; A61P; A61P11/00; A61P11/08

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 43 words
A pharmaceutical composition in unit dosage form for the treatment of inflammatory changes and diseases of the bronchial mucosa comprising of between 100 and 200 mg of etofylline; vitamin A up to about 50,000 I.U. and between 50 and 70 mg of magnesium.
Claim 2
Dependent Claim 43 words
A pharmaceutical composition in unit dosage form for the treatment of inflammatory changes and diseases of the bronchial mucosa comprising of between 100 and 200 mg of etofylline; vitamin A up to about 50,000 I.U. and between 50 and 70 mg of magnesium.
Claim 3
Independent Claim 47 words
A method for treatment of inflammatory changes and diseases of the bronchial mucosa in humans comprising the administration to a human in need thereof of a daily dosage of about 200 mg of etofylline, up to 50,000 I.U. of vitamin A and about 70 mg of magnesium.
Claim 4
Independent Claim 47 words
A method for treatment of inflammatory changes and diseases of the bronchial mucosa in humans comprising the administration to a human in need thereof of a daily dosage of about 200 mg of etofylline, up to 50,000 I.U. of vitamin A and about 70 mg of magnesium.

References Cited (Backward Citations)

US4246264A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-08-18 1990-02-17 1990-08-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-08-18 1994-02-17 1994-08-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-08-18 1998-02-17 1998-08-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag